Last $9.00 USD
Change Today +0.20 / 2.27%
Volume 189.6K
LBIO On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

lion biotechnologies inc (LBIO) Snapshot

Open
$8.85
Previous Close
$8.80
Day High
$9.94
Day Low
$8.79
52 Week High
04/4/14 - $11.25
52 Week Low
02/6/14 - $4.75
Market Cap
296.3M
Average Volume 10 Days
44.8K
EPS TTM
--
Shares Outstanding
32.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LION BIOTECHNOLOGIES INC (LBIO)

Related News

No related news articles were found.

lion biotechnologies inc (LBIO) Related Businessweek News

No Related Businessweek News Found

lion biotechnologies inc (LBIO) Details

Lion Biotechnologies, Inc., a development stage biotechnology company, develops T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate includes a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop and manufacture certain proprietary autologous TILs adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer; a cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and a process development and scale-up consulting agreement with Lonza Walkersville, Inc. to manufacture TILs. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in Woodland Hills, California.

8 Employees
Last Reported Date: 11/13/14
Founded in 2007

lion biotechnologies inc (LBIO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

lion biotechnologies inc (LBIO) Key Developments

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma

Lion Biotechnologies, Inc. announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct a Phase 2 clinical trial of the company's lead product candidate, LN-144, in the treatment of patients with refractory metastatic melanoma. LN-144 is a cell product of autologous tumor infiltrating lymphocytes (TIL) derived from the patient's tumor.

Lion Biotechnologies, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 03:00 PM

Lion Biotechnologies, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 03:00 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Elma S. Hawkins, Chief Executive Officer, President and Director.

Lion Biotechnologies, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Lion Biotechnologies, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LBIO:US $9.00 USD +0.20

LBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LBIO.
View Industry Companies
 

Industry Analysis

LBIO

Industry Average

Valuation LBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 15.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LION BIOTECHNOLOGIES INC, please visit www.genesis-biopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.